FX.co ★ Pfizer Q4 Results Beat Market; Confirms FY25 Outlook - Update

Pfizer Inc. (PFE), a leading pharmaceutical company, has announced a profit in its fourth quarter, rebounding from a previous year's loss, and has reaffirmed its fiscal outlook for 2025. As of the pre-market trading session on the NYSE, Pfizer's stock increased by 2.5%, reaching $26.85.

For fiscal year 2025, Pfizer maintains its forecast for adjusted earnings per share (EPS) within the range of $2.80 to $3.00. Wall Street analysts, on average, anticipate an EPS of $2.93, excluding any special items.

Revenue projections for 2025 remain between $61 billion and $64 billion, while market expectations center around $63 billion. Pfizer reiterated its annual guidance for 2025, initially presented on December 17, projecting an operational growth in adjusted EPS of 10% to 18% year-over-year and operational revenue growth ranging from flat to 5%, both relative to the midpoint of the 2024 baseline guidance.

In fiscal year 2024, Pfizer achieved an adjusted EPS of $3.11, with revenues amounting to $63.6 billion. The company also expects to realize approximately $4.5 billion in net cost savings from an ongoing cost realignment initiative by the end of 2025.

In the fourth quarter, Pfizer reported a net income of $410 million, or $0.07 per share, contrasting with the previous year's net loss of $3.369 billion, or $0.60 per share. Adjusted earnings for the quarter stood at $3.592 billion, or $0.63 per share, significantly up from $593 million, or $0.10 per share, a year earlier. Analysts had projected quarterly earnings of $0.46 per share.

Revenue for the quarter reached $17.763 billion, up from $14.570 billion in the same period of the previous year, surpassing the market's anticipated $17.26 billion. This 22% revenue increase was mainly driven by an operational growth of 21%, attributed to a one-time non-cash Paxlovid revenue reversal of $3.5 billion recorded in the fourth quarter of 2023. Excluding contributions from Paxlovid and Comirnaty, revenue amounted to $13.7 billion, marking an 11% operational increase compared to the previous year's quarter.